Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.

Recruiting now

Conditions studied: Cardiotoxicity

In brief

To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.

Key facts

Study ID

NCT07663357

Run by

Beneficência Portuguesa de São Paulo

People needed

1000

Starts

2026-05-11

Expected to finish

2029-12-30

Last updated by the study team

2026-06-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a confirmed diagnosis of breast cancer who are scheduled to initiate treatment with anthracyclines and/or HER2-targeted therapies (anti-HER2 therapies).

You may not qualify if…

• Patients with a left ventricular ejection fraction (LVEF) < 50%;
• Patients who have undergone chemotherapy and/or radiotherapy within the previous year;
• Patients with chronic kidney disease and a glomerular filtration rate (GFR) < 30 mL/min/1.73 m²;
• Patients with uncontrolled hypertension;
• Patients with complex congenital heart disease.

Where it is running

• Hospital BP - A Beneficência Portuguesa de São Paulo — São Paulo, São Paulo, Brazil (enrolling)
• Instituto do Câncer do Ceará — Fortaleza, Ceará, Brazil
• Complexo Hospitar HUOC/PROCAPE — Recife, Pernambuco, Brazil
• Universidade Federal de Santa Catarina — Florianópolis, Santa Catarina, Brazil
• Hospital Beneficente UNIMAR — Marília, São Paulo, Brazil
• FAMERP - Faculdade de Medicina de São José do Rio Preto — São José do Rio Preto, São Paulo, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.